Hong Thai Pham, CEO, BioNet commented: “We are very pleased to be collaborating with BIA Separations / Sartorius in developing and tech-transferring optimized mRNA vaccine manufacturing processes.

Phillippe Guillot-Chene, CEO of BioNet Europe, added, “We believe that BioNet’s RPV represents a transformative vaccine for preventing pertussis disease.

More information: Gretel Monreal et al, Feasibility Testing of the Bionet Sonar Ultrasound Transcutaneous Energy Transmission (UTET) System for Wireless Power and Communication of a LVAD ...